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Introduction: Repetitive episodes of ischemia and reperfusion (I/R) are a cardinal feature of the pathogenesis of
systemic sclerosis (SSc), which precedes tissue fibrosis. The complement system is a key mediator of tissue damage
after I/R, primarily by activation of the lectin pathway. This study investigated whether serum levels and polymorphisms
of mannose-binding lectin (MBL) and ficolin-2 (FCN2), two pattern recognition receptors of the lectin pathway, are
associated with the predisposition to and clinical features of SSc.
Methods: A case-control study was undertaken involving 90 patients with SSc from a single SSc outpatient clinic and
90 age- and sex-matched blood donors. MBL and FCN2 levels and polymorphisms were measured in both groups, and
in cases correlated with clinical data.
Results: MBL levels and genotypes were equally distributed in cases and controls while there were some significant
differences in FCN2 polymorphisms. Median MBL levels were higher in SSc cases with diffuse disease compared with
controls (2.6 versus 1.0 μg/ml, P <0.001).
In cases, higher MBL levels were associated with the presence of clinical findings associated with vascular dysfunction
and local tissue damage (digital ulcers, calcinosis and pitting). Moreover, MBL levels were associated with fibrotic
disease manifestations as evidenced by the presence of diffuse disease (median 2.6 versus 0.8 μg/ml, P = 0.002), the
modified Rodnan skin score (r = 0.39, P <0.001), and interstitial lung disease as measured by forced vital capacity
(r = −0.33, P = 0.001). Importantly, MBL levels also correlated with the Scleroderma Health Assessment Questionnaire
scores (r = 0.33, P = 0.002). The results for FCN2 levels were less striking. Phenotypic MBL results were largely confirmed
by analysis of MBL polymorphisms. MBL levels were not associated with the presence of autoantibodies or
hypocomplementaemia.
Conclusions: Overall, predisposition to SSc was not influenced by the lectin pathway of complement in our matched
case-control study. However, our preliminary data suggest that MBL, and to a lesser extent FCN2, may modulate disease
manifestations of SSc, particularly in diffuse cutaneous disease.Introduction
Systemic sclerosis (SSc) is a complex autoimmune dis-
ease associated with a high morbidity and mortality [1],
in which vascular injury, extensive fibrosis, and autoanti-
bodies are the cardinal pathologic features. The extent
of cutaneous fibrosis is used to classify SSc patients into* Correspondence: josahhar@bigpond.com
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stated.two major subgroups: limited cutaneous and diffuse cu-
taneous SSc [2]. Genetic factors have been demonstrated
to influence disease susceptibility as well as patterns of
disease expression [3]. However, the pathogenesis of SSc
is complex and remains incompletely understood with
much of the research having been focused on fibroblast
activation and fibrosis rather than vascular dysfunction.
Intriguingly, the concept of vascular injury as a funda-
mental element in the pathogenesis of SSc was suggested
more than 120 years ago [4]. Recent evidence supports
the hypothesis that microvascular injury is an early eventLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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[5]. Initially, an undetermined triggering event causes
mild oxidative stress, coinciding with perivascular in-
flammation and endothelial dysfunction. Repetitive epi-
sodes of ischemia and reperfusion (I/R) and persistent
oxidative stress are responsible for progressive endothe-
lial dysfunction, activation of vascular mesenchymal cells
and leakage of growth factors leading to progressive
tissue fibrosis and finally late organ dysfunction [6]. Im-
portantly, vascular damage occurs in virtually all organs
with cardiopulmonary involvement being responsible for
the majority of disease-related mortality [7]. Later in the
disease, inflammation subsides with atrophy and organ de-
rangement prevailing. Apart from the adaptive immune
system, components of innate immunity have been impli-
cated in the pathogenesis of SSc including the comple-
ment system, an ancient cascade of circulating serum
proteins and proteases [8,9].
The lectin pathway of complement is activated after
binding of mannose-binding lectin (MBL) or ficolins
(ficolin-1, -2, and -3) to carbohydrate patterns, acetyl
groups or immunoglobulin M (IgM) bound to antigens on
pathogens and dying cells, with subsequent activation of
MBL-associated serine protease (MASP)-1 and -2 and
assembly of the C3 convertase [10]. Interestingly, a direct
link between the MBL-MASP complex and the coagula-
tion cascade has been recently shown without the involve-
ment of downstream complement components [11,12].
The serum concentration of these pattern recognition re-
ceptors (PRR) vary between individuals, with MBL sho-
wing the greatest difference (from undetectable to about
10 μg/mL), as a result of polymorphisms in the exon and
promoter region of the MBL2 gene on chromosome 10
[13]. Notably, the prevalence of moderate to severe MBL
deficiency is as high as 30% in most populations investi-
gated to date [13]. Similarly, a number of major polymor-
phisms have been described for the ficolin-2 gene (FCN2)
with a much weaker genotypic/phenotypic relationship
than is the case for MBL [14].
MBL deficiency has been implicated as a risk factor in
other autoimmune diseases such as systemic lupus ery-
thematosus [15]. In addition, several recent studies have
acknowledged the important role of MBL and ficolin-2 in
I/R injury [16,17]. MBL and the lectin complement path-
way seem to be an essential component of the inflamma-
tory process augmenting I/R injury in various organs,
such as the heart and the brain [18,19]. Conversely, bloc-
kade of MBL and lectin pathway activation results in
diminished tissue injury [18,20,21]. In line, human MBL
deficiency was found to be associated with a significant re-
duction in morbidity and mortality after acute myocardial
infarction or acute ischemic stroke, respectively [22,23].
Evidence for an involvement of MBL or the lectin path-
way in the pathogenesis of SSc is lacking. To address thisquestion, we investigated the association of serum levels
and polymorphisms of two PRRs of the lectin pathway,
MBL and ficolin-2, with predisposition to and clinical fea-
tures of SSc. Given the importance of vascular I/R injury
in SSc on the one hand, and the central involvement of
the lectin pathway in I/R injury on the other hand, we
hypothesized that the presence of MBL deficiency and
polymorphisms in the MBL2 and FCN2 genes are asso-
ciated with a reduced risk of SSc and less severe disease
manifestations in SSc patients.
Methods
Participants
We conducted a matched case-control and cross-sectional
study involving 90 patients with SSc or mixed connective
tissue disease (MCTD) from a single SSc outpatient clinic
(Monash Health) and 90 age- and sex-matched blood
donors. This study has been approved by the Human
Research and Ethics Committee of Monash Health,
Melbourne Health and the Australian Red Cross Blood
Service.
Clinical and corresponding laboratory data and stored
blood samples were available from SSc patients who had
been previously recruited at a single SSc outpatient
clinic as part of the Australian Scleroderma Cohort
study (ASCS), an ongoing longitudinal cohort study of
predictive factors for the development of cardiopulmo-
nary complications and outcomes of therapy in SSc. Par-
ticipants had consented to collection, storage and use of
blood samples and data for future SSc-related research
projects at inclusion into the ASCS. Age- (within five
years) and sex-matched controls were selected from a
previous cohort of 426 healthy blood donors (Australian
Red Cross Blood Service (ARCBS), Brisbane, Australia)
for whom informed consent was waived by the Human
Research and Ethics Committee of the ARCBS (ethics
approval 2011#08).
SSc patients were over 18 years of age with a clinical
diagnosis of SSc according to the American College of
Rheumatology criteria [24] or the LeRoy and Medsger cri-
teria [25] and were classified using the LeRoy criteria for
limited or diffuse SSc [2]. Patients were diagnosed with
MCTD according to the Alarcon-Segovia criteria [26].
Clinical and laboratory data (that is C-reactive protein
(CRP), creatinine, erythrocyte sedimentation rate (ESR),
complement C3 and C4) and serum samples collected at
the most recent annual visit (April 2012 till April 2013)
were used for the purpose of this study. Clinical data in-
cluded past medical history, past and current medication,
current skin findings, organ involvement, results from
pulmonary function testing, transthoracic echocardiogram
and the six-minute walk test, modified Rodnan skin
score (mRSS), EULAR Scleroderma Trial and Research
Group (EUSTAR) Systemic Sclerosis Activity Score, and
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HAQ) score. Results from autoantibody screening were
available from the first study visit.
Pulmonary arterial hypertension (PAH) was diagnosed
based on right heart catheterisation findings of a mean
pulmonary artery pressure of greater than 25 mm Hg at
rest or greater than 30 mm Hg on exercise, in the pre-
sence of a pulmonary capillary wedge pressure of less than
18 mm Hg. Interstitial lung disease (ILD) was defined as
the presence of characteristic abnormalities on high-
resolution computed tomography (CT) chest scan, and
scleroderma renal crisis was defined as the presence of at
least two of: new-onset hypertension, microangiopathic
anemia or rising creatinine. Immunosuppressive medica-
tion was defined as current use of prednisolone (>5 mg
daily), methotrexate, azathioprine, mycophenolate mofetil,
cyclosporine A, or cyclophosphamide. Disease duration
was calculated from the onset of the first non-Raynaud’s
phenomenon symptom.
Definition of endpoints
The main aim of this study was to compare serum MBL
levels and the frequency of MBL deficiency in SSc pa-
tients with age- and sex-matched controls. Additional
aims included investigating the association of MBL and
ficolin-2 levels and polymorphism with disease manifes-
tations and autoantibodies in SSc cases only.
Determination of MBL and ficolin-2 plasma levels
Quantification of MBL serum levels was performed by
an investigator blinded to clinical data using a mannan-
binding enzyme-linked immunosorbent assay (ELISA) as
previously described [27]. Briefly, mannan-coated mi-
crotitre plates were incubated with samples at 1:25 and
1:100 dilutions for 90 minutes at room temperature
followed by detection of bound MBL with a biotinylated
monoclonal anti-MBL antibody (HYB 131-01, BioPorto
Diagnostics, Hellerup, Denmark). MBL deficiency was de-
fined as serum level <0.5 μg/mL. Ficolin-2 serum levels
were quantified using a commercially available ELISA kit
(Hycult, Udin, The Netherlands). As different kinds of
analytic tubes were used in cases and controls, ficolin-2
levels were only determined in cases (with the same
analytic tube used for all cases) in agreement with recent
studies showing significant differences in ficolin-2 levels
depending on the blood collection system [28,29].
MBL2 and ficolin-2 genotyping
DNA lysates were prepared according to the manufac-
turer’s instructions (TaqMan Sample-to-SNP, Life Tech-
nologies, Mulgrave, VIC, Australia). Subsequently, MBL2
and FCN2 promoter and exon polymorphisms were deter-
mined by allele-specific polymerase chain reaction (PCR)
using TaqMan fluorescent probes (TaqMan genotypingassays, Life Technologies) as described elsewhere [30]. For
assay details, see Table S1 in Additional file 1.
MBL2 genotypes were classified as low (XA/YO, YO/
YO), intermediate (XA/XA, YA/YO) or high (YA/YA, XA/
YA) producing genotypes according to published literature
[31], with exon variant alleles collectively designated as
O and the wild-type gene as A, and the promoter variant
allele and the wild-type gene designated as X and Y, re-
spectively. FCN2 promoter and exon polymorphisms were
analyzed separately and combined as haplotypes [32].
Statistical analysis
We used the chi-square test for comparisons of categor-
ical variables and allele and genotype frequencies and to
check for Hardy-Weinberg equilibrium. To investigate
MBL and ficolin-2 as potential risk factors for SSc,
matched univariate analysis was performed by running
conditional logistic regression on one variable at a time
with SSc as the dependent variable. In addition, Wil-
coxon signed-rank test was applied to compare MBL
levels in cases and matched controls. Haplotype frequen-
cies were analyzed by expectation-maximum algorithm.
Differences in disease severity and organ involvement
according to MBL and ficolin-2 levels were analyzed
using the Mann-Whitney U test (with reporting of me-
dian and interquartile range (IQR) due to the non-
Gaussian distribution of MBL levels) and the Student’s
t test (with reporting of mean and standard deviation
(SD)), respectively. Continuous variables were correlated
with MBL and ficolin-2 levels using the Spearman rank
and Pearson correlation tests, respectively. Linear regres-
sion analysis was used to estimate the association of
MBL levels with mRSS and SSc HAQ score after adjust-
ment for age, sex, presence of ILD and PAH.
All testing was two-tailed. Haplotype and linkage dis-
equilibrium analysis was carried out with the Haploview
program (version 4.2, The Broad Institute, Cambridge,
MA, USA). All other analyses were performed with SPSS
statistical software, version 17.0 (SPSS Inc., Chicago, IL,
USA).
Results
Demographic, clinical and lectin pathway characteristics
of cases and controls
The study population consisted of 90 SSc cases and 90 age-
and sex-matched blood donors, with population demo-
graphics and clinical characteristics outlined in Table 1.
Mean age (SD) was 60 (15) and 59 (16) years in cases and
controls, respectively, and 78 (87%) were female in both
groups. Cases were classified as limited and diffuse SSc in
69% and 26%, respectively, with the remaining patients
having been diagnosed with MCTD (4/90) or sine sclero-
derma (1/90). Anti-centromere antibodies were present in
38/90 cases and anti-Scl-70 antibodies in 17/90 cases.
Table 1 Characteristics of cases and controls
Characteristics Cases Controls
(n = 90) (n = 90)
Female, n (%) 78 (87) 78 (87)





Duration of disease (years), mean (SD) 14.3 (10.3)
SSc subtype, n (%)
Diffuse disease 23 (26)
Limited disease 62 (69)
Sine 1 (1)
Mixed connective tissue disease 4 (4)
Autoantibodies, n (%)
Anti-topoisomerase I (Scl-70) 17 (19)
Anti-centromere 38 (42)
Anti-RNA polymerase III 8 (9)
Organ involvement, n (%)
Bowel dysmotility 9 (10)
Pulmonary arterial hypertension 8 (9)
Interstitial lung disease 41 (46)
Renal crisis 4 (4)
Gastroesophageal reflux disease 83 (92)
Disease activity/severity
Active digital ulcers, n (%) 13 (14)
mRSS, mean (SD) 8.9 (7.3)
SSc HAQ, mean (SD) 20.5 (13.4)
EUSTAR SSc activity score, mean (SD) 2.2 (1.7)
Immunosuppressive agents, n (%) 28 (31)
Past treatment with iloprost, n (%) 17 (19)
FVC (% predicted), mean (SD) 91.5 (22.5)
DLCO (% predicted), mean (SD) 58.5 (18.8)
6MWD (meter), mean (SD) meters 471.7 (126.1)
6MWD, six-minute walk distance; DLCO, diffusing capacity of the lung for
carbon monoxide; EUSTAR, EULAR Scleroderma Trials and Research Group;
FVC, forced vital capacity; mRSS, modified Rodnan skin score; SD, standard
deviation; SSc, systemic sclerosis; SSc HAQ, Scleroderma Health Assessment
Questionnaire.
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most frequent organ involvement (41/90), with PAH,
myocardial involvement and scleroderma renal crisis en-
countered less frequently.
MBL2 and FCN2 allele frequencies at all 10 positions
were in agreement with the predicted Hardy-Weinberg
equilibrium (data not shown). The frequency of MBL2
mutations at four positions, MBL2 genotypes and MBL
deficiency (defined as serum levels <0.5 μg/mL) wassimilar in SSc cases and controls, as were overall MBL
serum levels (Table 2). However, MBL serum levels were
significantly higher in diffuse SSc patients compared to
limited SSc cases and controls (Figure 1). In line with
this, MBL deficiency was rare in diffuse compared to
limited SSc patients or controls (2 (9%) vs. 36 (39%) vs.
25 (28%), P = 0.02), as were low-producing MBL2 geno-
types (1(4%) vs. 17 (25%) vs. 18 (20%), P = 0.1).
Regarding FCN2 polymorphisms, there were only
minor differences at two positions (FCN2 -4 and +6359)
in cases and controls (Table 3).
Association of MBL and ficolin-2 with SSc disease activity,
inflammatory markers and autoantibodies
Apart from MBL, mean ficolin-2 levels were also sig-
nificantly higher in diffuse SSc patients compared to
limited and sine scleroderma SSc patients (0.71 (0.38)
vs. 0.51 (0.32), P = 0.02), in line with a more frequent
detection of the FCN2 wild-type haplotype GGAACG
(−986G > A, −602G >A, −557A >G, −4A >G +6359 C > T
and +6424 G > T) in diffuse SSc patients (51% vs. 30%,
P = 0.03).
MBL levels were significantly elevated in SSc patients
with examination findings of pitting, calcinosis and di-
gital ulcers (but not with telangiectasia, pulp atrophy
and nailfold capillary dilatation), which was not the case
for ficolin-2 levels (Table 4). Of note, higher MBL and
ficolin-2 levels were also observed in patients who had
received iloprost infusions for Raynaud phenomenon
(MBL: median 2.78 (0.84 to 4.31) vs. 0.89 (0.25 to 2.1),
P = 0.007; ficolin-2: mean 0.71 (0.35) vs. 0.53 (0.34),
P = 0.05), and MBL high-producing genotypes were also
more common in this group (13 (77%) vs. 35 (48%),
P = 0.06). In contrast, there was no relationship of these
lectin pathway proteins with the use of calcium-channel
blockers (data not shown).
In keeping with a potential association of MBL with cer-
tain SSc disease manifestations, MBL levels also correlated
with the mRSS and the SSc HAQ score (Figure 2A, B),
again supported by genotypic data showing higher mRSS
and SSc HAQ scores in cases with wild-type MBL2 geno-
types vs. intermediate-producing vs. low-producing geno-
types, respectively (mean mRSS score (SD) 11 (9) vs. 7 (5)
vs. 5 (3), P <0.01; mean SSc HAQ score 23 (14) vs. 18 (15)
vs. 16 (8), P = 0.07). After adjustment for sex, age, pres-
ence of ILD and PAH, MBL levels remained independ-
ently associated with the degree of skin involvement as
measured by the mRSS, and with the degree of functional
impairment as assessed by the SSc HAQ. The average
mRSS and SSc HAQ score increased by 1.7 and 3.6 for
every 1 μg/mL increase in MBL serum levels (standard
error 0.46 and 0.91, 95% CI 0.73 to 2.56 and 1.63 to 5.24,
respectively, P <0.001 for both analyses), respectively. In
contrast, ficolin-2 levels did not correlate with the mRSS
Table 2 Analysis of MBL2 geno- and phenotypes in SSc cases and controls
Variables Cases Controls Univariate matched analysis
(n = 90) (n = 90) OR (95% CI) P value
MBL2 exon variants, n (%)
A/A 56 (62) 59 (66) Reference
A/O 30 (33) 25 (28) 1.2 (0.7-2.3) 0.5
O/O 4 (4) 6 (7) 0.6 (0.1-3.1) 0.5
MBL2 promoter variant, n (%)
Y/Y 46 (51) 47 (52) Reference
Y/X 36 (40) 38 (42) 1.0 (0.6-1.7) 1
X/X 8 (9) 5 (6) 1.7 (0.5-6.2 0.4
MBL2 genotypes, n (%)
High producing 48 (53) 54 (60) Reference
Intermediate producing 24 (27) 18 (20) 1.5 (0.7-3.0) 0.3
Low producing 18 (20) 18 (20) 1.1 (0.5-2.5) 0.8
MBL levels (μg/ml), median (IQR) 1.1 1.0 1.3 (1.0-1.7)a 0.06
MBL <0.5 μg/ml, n (%) 62 (69) 65 (72) 1.2 (0.6-2.5) 0.6
MBL2 genotypes were classified as low- (XA/YO, YO/YO), intermediate- (XA/XA, YA/YO) or high- (YA/YA, XA/YA) producing genotypes with exon variant alleles
collectively designated as O and the wild-type gene as A, and the promoter variant allele and the wild-type gene designated as X and Y, respectively. aPer 1 μg/ml
increase in MBL serum levels. CI, confidence interval; IQR, interquartile range; MBL, mannose-binding lectin; OR, odds ratio; SSc, systemic sclerosis.
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was even stronger when limiting the analysis to diffuse
SSc patients (r = 0.48, P = 0.02). MBL levels but not
ficolin-2 levels correlated with the EUSTAR Systemic
Sclerosis Activity Score in diffuse SSc patients (r = 0.49, P
= 0.02).
There was no association of autoantibodies, levels of in-
flammatory markers (CRP, ESR) and complement C3/C4
with MBL/ficolin-2 levels or genotpyes (data not shown).Figure 1 Serum mannose-binding lectin levels in SSc cases and
healthy controls. MBL levels were analyzed in SSc cases overall and
stratified according to skin involvement (limited cutaneous vs.
diffuse cutaneous. Horizontal bars indicate median and 25 to 75
percentiles. Dc SSc, diffuse cutaneous systemic sclerosis; Lc SSc,
limited cutaneous systemic sclerosis; MBL, mannose-binding lectin.In addition, neither MBL nor ficolin-2 levels or genotypes
correlated with disease duration in the whole cohort, or
when analysis was limited to diffuse SSc patients or those
with a disease duration of <5 years vs. ≥5 years (data not
shown).Association of MBL and ficolin-2 with SSc organ
involvement
Higher ficolin-2 levels were associated with bowel dys-
motility, ILD and a history of scleroderma renal crisis
(but not PAH) with a similar non-significant trend in
MBL levels (Table 4). In line, the FCN2 wild-type haplo-
type GGAACG was encountered more frequently in pa-
tients with ILD (50% vs. 26%, P = 0.02).
Regarding ILD, MBL and ficolin-2 levels were inversely
correlated with forced vital capacity (FVC) in the whole
cohort (Figure 2C), and patients with low-producing
MBL2 genotypes had significantly higher FVC values
(mean 103 (20), vs. 89 (22), P = 0.02). The correlation of
MBL with FVC was even more pronounced when limiting
the analysis to diffuse SSc patients (r = −0.55, P = 0.008).
In addition, higher MBL and ficolin-2 levels were ob-
served in SSc patients with a reduced FVC <70% (median
MBL levels 2.88 (1.66 to 4.45) vs. 0.85 (0.18 to 2.0),
P = 0.001; mean ficolin-2 levels 0.73 (0.39) vs. 0.52 (0.32),
P = 0.02). Of note, all patients with a FVC <50% had
a high-producing MBL2 genotype. However, MBL and
ficolin-2 levels did not correlate with diffusion capacity of
the lung for carbon monoxide or six-minute walk distance
(data not shown).
Table 3 Analysis of FCN2 polymorphisms in SSc cases and controls
Variables Cases Controls Univariate matched analysis
(n = 90) (n = 90) OR (95% CI) P value
FCN2 promoter variants, n (%)
FCN2 -986, n (%)
G/G 27 (30) 22 (24) Reference
G/A 39 (43) 44 (49) 0.7 (0.3-1.5) 0.4
A/A 24 (27) 24 (27) 0.8 (0.4-1.7) 0.6
FCN2 - 602, n (%)
G/G 57 (63) 63 (70) Reference
G/A 25 (28) 23 (26) 1.1 (0.6-2.3) 0.7
A/A 8 (9) 4 (4) 2.0 (0.6-6.7) 0.25
FCN2 - 557, n (%)
A/A 65 (72) 76 (84) Reference
A/G 23 (26) 13 (14) 2.1 (1.0-4.7) 0.07
G/G 2 (2) 1 (1) 2 (0.2-22.0) 0.6
FCN2 - 4, n (%)
A/A 53 (59) 41 (46) Reference
A/G 35 (39) 41 (46) 0.7 (0.4-1.2) 0.18
G/G 2 (2) 8 (9) 0.2 (0.04-0.99) 0.048
FCN2 exon variants, n (%)
FCN2 + 6359, n (%)
C/C 49 (54) 40 (44) Reference
C/T 39 (44) 40 (44) 0.8 (0.4-1.4) 0.4
T/T 2 (2) 10 (11) 0.2 (0.04-0.8) 0.03
FCN2 + 6424, n (%)
G/G 65 (72) 74 (82) Reference
G/T 22 (24) 15 (17) 1.6 (0.8-3.2) 0.2
T/T 3 (3) 1 (1) 3.4 (0.4-33.0) 0.3
FCN2 haplotypes, n (%)
GGAACG 31 (35) 37 (41) Reference
AGAGTG 18 (20) 26 (30) 0.6 (0.4-1.1) 0.1
AAAACG 19 (22) 14 (15) 1.4 (0.8-2.4) 0.3
GGGACT 11 (13) 7 (7) 1.7 (0.7-3.8) 0.2
AGAACG 4 (4) 2 (2) 1.7 (0.5-5.0) 0.4
CI, confidence interval; FCN2, ficolin-2; OR, odds ratio; SD, standard deviation; SSc, systemic sclerosis.
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dian MBL levels in SSc patients with World Health
Organization (WHO) functional class III/IV compared
to I/II (2.39 (1.13 to 3.12) vs. 0.81 (0.19 to 2.24),
P = 0.02) in accordance with a higher frequency of MBL2
high-producing genotypes (15 (75%) vs. 33 (47%), P = 0.03)
in the same group. There was no difference in MBL or
ficolin-2 polymorphisms/levels with respect to the use of
pulmonary vasodilator therapy (data not shown).
Patients currently on immunosuppressive medication
had higher median MBL (2.10 (0.80 to 3.13) vs. 0.78(0.10 to 2.13, P = 0.005) and mean ficolin-2 levels (0.67
(0.36) vs. 0.52 (0.32), P = 0.05), which was in agreement
with MBL2 genetics (high-producing genotypes: 21(75%)
vs. 24 (45), P = 0.007).
Discussion
SSc is a complex and heterogeneous disease charac-
terized by fibrosis, vascular and immune dysfunction.
Data from several candidate gene [3] and genome-wide
association studies [33-35] (GWAS) suggest that genetic
factors may influence not only SSc susceptibility but also
Table 4 Association of MBL and ficolin-2 with SSc disease manifestations
Variables MBL levels (μg/ml), median (IQR) MBL2 low-producing genotype, n (%) Ficolin-2 levels (μg/ml), mean (SD)
Skin manifestations
Calcinosis (yes vs. no) 2.1 (0.7-3.2) vs. 0.8 (0.1-2.1) 2 (7) vs. 16 (27) 0.6 (0.3) vs. 0.6 (0.3)
P value 0.005 0.02 0.9
Pitting (yes vs. no) 1.8 (0.5-3.0) vs. 0.8 (0.1-1.9) 6 (13) vs. 12 (29) 0.6 (0.4) vs. 0.5 (0.3)
P value 0.007 0.06 0.2
Digital ulcers (yes vs. no) 2.7 (1.0-4.1) vs. 1.0 (0.2-2.3) 1 (8) vs. 17 (22) 0.6 (0.4) vs. 0.6 (0.3)
P value 0.01 0.2 0.5
Organ involvement
PAH (yes vs. no) 1.7 (0.3-3.8) vs. 1.1 (0.3-2.6) 1 (13) vs. 17 (21) 0.5 (0.2) vs. 0.6 (0.4)
P value 0.5 1 0.6
ILD (yes vs. no) 1.7 (0.5-2.9) vs. 0.9 (0.2-2.1) 6 (15) vs. 12 (25) 0.7 (0.3) vs. 0.5 (0.3)
P value 0.11 0.3 0.04
Renal crisis (yes vs. no) 1.7 (0.2-4.1) vs. 1.1 (0.3-2.6) 1 (25) vs. 17 (20) 1.0 (0.3) vs. 0.6 (0.3)
P value 0.6 1 0.01
Bowel dysmotility (yes vs. no) 3.1 (0.8-4.2) vs. 1.1 (0.3-2.4) 1 (11) vs. 17 (21) 0.6 (0.3) vs. 0.4 (0.2)
P value 0.14 0.7 0.04
ILD, interstitial lung disease; IQR, interquartile range; MBL, mannose-binding lectin; PAH, pulmonary arterial hypertension; SD, standard deviation; SSc,
systemic sclerosis.
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such as limited or diffuse SSc. Given the role of the lec-
tin pathway of complement in general, and MBL in par-
ticular in tissue damage related to vasculopathy in vitro
and in vivo, we sought to determine a potential link bet-
ween the lectin pathway and the predisposition to and
severity of SSc in a well-characterized Australian SSc
cohort.
While MBL levels and frequency of MBL and FCN2
polymorphisms were similar in controls and the entire
SSc cohort, our preliminary data indicate that MBL defi-
ciency (and potentially FCN2 mutations) might be a pro-
tective factor for the development of diffuse SSc. This
finding is not necessarily in contradiction to previous
GWAS, which have not identified MBL or ficolin-2 as
susceptibility genes, as limitations of GWAS include
their single-variant-centred approach and lack of pheno-
typic data. In the case of MBL this might be important,
as MBL levels are the result of a complex interplay bet-
ween several genetic variants in the promoter and exon
region [13] and physiologic variables such as thyroid
[36] and liver function [37]. With a much weaker geno-
typic/phenotypic relationship, this might be even more
relevant in the case of ficolin-2 [14]. As our sample size
was limited, future studies are needed to clarify the asso-
ciation of MBL with diffuse SSc.
MBL deficiency was not associated with anti-Scl-70
autoantibodies commonly detected in diffuse SSc patients,
which points to a pathogenesis of MBL-mediated tissue
damage that is independent of autoantibody involvement.While not investigated in SSc experimental models,
evidence from comprehensive animal and human studies
suggests that MBL-mediated damage in I/R injury is
caused by binding of MBL to IgM on stressed endothelial
and parenchymal cells causing apoptosis [38], activation
of the complement and the coagulation cascade (via
MASP-1) and recruitment of inflammatory cells [39]. As-
suming this analogy, we propose a similar pathogenesis in
chronic cutaneous microvascular injury in SSc patients.
Previous studies have demonstrated decreased expression
of endothelial complement regulatory proteins on the one
hand [40] and activation of downstream complement
components on the other hand [41] in skin biopsies of
SSc patients, even in non-involved skin. However, it re-
mains to be determined if the lectin pathway is primarily
responsible for the observed cutaneous complement acti-
vation in SSc.
Additionally, we have investigated the association of
MBL and ficolin-2 with SSc disease manifestations and se-
verity. In agreement with our a priori hypothesis, MBL
levels were significantly higher in patients with diffuse SSc
vs. limited/sine SSc patients, in patients with vascular dis-
ease manifestations, and in patients on immunosup-
pressive medication or with a history of iloprost infusions
for Raynaud phenomenon. The latter may be regarded as
a surrogate for more severe disease manifestations as SSc
patients with more severe organ disease or digital ulcers
are more likely to receive immunosuppressive medication
and iloprost infusions, respectively. In addition, MBL
levels correlated with extent of skin involvement as
Figure 2 Correlation of serum MBL levels with activity and
extent of disease in SSc cases. (A) Correlation with extent of skin
involvement as assessed by the modified Rodnan skin score (mRSS).
(B) Correlation with extent of functional disability as assessed by
the Scleroderma Health Assessment Questionnaire (SSc HAQ).
(C) Correlation with extent of pulmonary involvement as assessed
by forced vital capacity (FVC, % predicted). MBL, mannose-binding
lectin; SSc, systemic sclerosis.
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pairment as evaluated by the SSc HAQ. Our results were
also supported by genetic data with MBL2 polymorphisms
being rare in patients with diffuse SSc, extensive skin in-
volvement and higher disease activity. The association of
MBL levels with skin involvement and disease activity was
even more pronounced in diffuse SSc patients, lending
support to the hypothesis of SSc being a heterogenous dis-
ease with different genetic variants being implicated in
specific SSc subtypes [42]. In summary, MBL deficiency
seems to be a protective factor for the development of
peripheral vascular and skin manifestations in SSc, with
less striking results for ficolin-2.
Regarding organ involvement, we have observed sig-
nificant associations of higher ficolin-2 levels in SSc pa-
tients with pulmonary, bowel and renal involvement
with a similar non-significant trend in the case of MBL
levels. In addition, an inverse correlation of ficolin-2 and
MBL levels with FVC was observed, which was again
more pronounced in diffuse SSc patients. This is of im-
portance, as FVC is a validated predictor of long-term
progression of SSc-related ILD [43]. Recent evidence has
identified a central role of stressed or damaged endothe-
lial cells in the development of interstitial lung disease
through several different mechanisms, for example acti-
vation of the immune system [44]. Interestingly, over a
decade ago Collard et al. [45] demonstrated binding of
MBL to endothelial cells immediately after oxidative
stress with subsequent activation of the lectin pathway
of complement, which could be prevented by anti-MBL
monoclonal antibodies. Independent of downstream com-
plement activation, binding of MBL to stressed endothelial
cells might also induce platelet activation and amplifica-
tion of the coagulation cascade [11,12]. Our results sup-
port the hypothesis that endothelial cell dysfunction may
induce pulmonary inflammation and fibrosis and that this
process might be partially mediated by MBL and ficolin-2.
The fact that MBL and ficolin-2 levels did not corre-
late with inflammatory markers or complement activity
as measured by C3 and C4 levels points to a distinctive
response of the lectin pathway in SSc rather than a col-
lective, non-specific proinflammatory immune reaction
to endothelial stress. Further studies are needed to iden-
tify targets and mechanisms that might be involved in
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gans in SSc.
The discovery of MBL and ficolin-2 being associated
with specific clinical manifestations in SSc patients might
lead to new insights regarding pathogenesis and may fa-
cilitate the development of novel therapies that can be tar-
geted to specific subsets of SSc patients. Our results draw
attention to MBL and the lectin pathway as a promising
target for reducing vascular injury in SSc patients. In fact,
a powerful inhibitor of the lectin pathway that binds to
and inhibits MBL and MASP-2 already exists. Recombi-
nant human C1 inhibitor (rhC1INH) is a multiple-action-
multiple-target inhibitor that not only interferes with the
lectin pathway but also with C1 of the classical path-
way and the coagulation system [46]. Administration of
rhC1INH considerably ameliorated tissue damage in ex-
perimental renal and cerebral I/R injury [18,47]. However,
data on chronic vascular injury as seen in SSc is lacking.
This is the first study to determine serum levels and
polymorphisms of two PRP of the lectin pathway of
complement in SSc patients. Previous studies have ex-
clusively examined the activity of the classical or alterna-
tive pathway [9,48,49]. In a recent pilot study, Akamata
et al. determined MBL levels in 63 Japanese SSc patients
and 10 healthy controls [50]. MBL2/FCN2 genotypes
and ficolin-2 levels were not examined. While confirm-
ing our findings of a correlation of MBL levels with ex-
tent of skin involvement in diffuse SSc patients, they
found no association of MBL levels with pulmonary
function tests and clinical manifestations. In addition,
MBL levels were similar in diffuse SSc patients and con-
trols. These discrepancies might be related to the sample
size of this study (63 SSc cases and 10 controls) and the
difference in disease duration and ethnic background
[51], as our patients were mainly of Caucasian ethnicity
and had on average a longer disease duration.
Despite the precisely characterized prospective cohort,
the present study has limitations including the post hoc
analysis of a limited number of PRRs of the lectin path-
way, and the inclusion of patients with mainly late SSc
making the cohort prone to survival bias. Indeed, one
could argue that higher MBL/ficolin-2 levels are actually
protective, if SSc patients with MBL deficiency or low
ficolin-2 levels had died early in the disease. However,
MBL and ficolin-2 levels did not correlate with disease
duration and were similar in SSc patients with disease
duration of <5 years vs. ≥5 years in our cohort (data not
shown). In addition, of the only two patients that had
died since the last annual visit and were included in this
analysis, both had high MBL levels (>2.0 μg/mL). On the
other hand, the inclusion of patients with long-standing
disease offered the advantage to investigate the asso-
ciation of lectin pathway proteins with advanced/late
disease manifestations.We could not determine whether MBL and ficolin-2
have a similar impact early and late in the disease.
Ideally, future studies should include additional lectin
pathway proteins like ficolin-1/-3 and MASP-1/-2, and
evaluate the impact of the lectin pathway on disease mani-
festations over time. For example, it would be useful to de-
termine if initial MBL and fioclin-2 levels can be used as a
predictor for progression of SSC-related ILD as measured
by FVC. Although our analysis of the importance of MBL
and ficolin-2 in SSc is the largest to date, its significance is
limited due to a small sample size. Nevertheless, validity
of our results is supported by agreement of phenotypic
and genotypic data, in particular with respect to MBL.
Pre-analytic issues precluded comparison of ficolin-2 le-
vels in cases and controls [28,29]. It remains speculative, if
minor variations in FCN2 haplotypes and polymorphisms
observed in cases and controls translate into a significant
difference in ficolin-2 levels, as the ficolin-2 genotypic/
phenotypic relationship is much weaker compared to
MBL [14]. Lastly, four patients with MCTD were analyzed
together with SSc patients as they had been included in
the Australian Scleroderma Cohort Study. Subsequent
studies investigating the lectin pathway of complement in
SSc should ideally only include individuals with diffuse
and limited SSc disease excluding MCTD patients.
Conclusions
In conclusion, our preliminary data suggest a strong as-
sociation of high MBL and to a lesser extent ficolin-2
levels with certain disease manifestations of SSc. While
not being able to demonstrate a causal relationship our
findings support the concept of a potential contribution
of the lectin pathway to chronic vascular injury and sub-
sequent fibrosis in SSc. If confirmed in future studies,
strategies focused on inhibition of MBL and the lectin
pathway might provide an additional targeted therapy to
supplement the limited therapeutic armamentarium cur-
rently available for treatment of patients with SSc.
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